Cytokinetics Fady Ibraham Malik sells 3,500 shares

Q: How many CYTK shares did Fady Ibraham Malik sell, and at what price?

Fady Ibraham Malik sold 3,500 shares at $62.93 per share on November 3, 2026. The sale was reported under a Rule 10b5-1 trading plan.

Q: What were the terms of the CYTK option exercise?

Fady Ibraham Malik exercised options covering 3,500 common shares at a $7.80 exercise price on November 3, 2026. The option record reported 12,886 underlying shares following the transaction.

Cytokinetics Inc. (CYTK) reported that Fady Ibraham Malik, EVP Research & Development, exercised options covering 3,500 common shares on November 3, 2026, at a $7.80 exercise price, and sold 3,500 shares at $62.93 per share that day under a Rule 10b5-1 plan.

Available on EDGAR 11/03/2026 - 04:38 PM EST Accepted by SEC EDGAR 11/03/2026 - 04:38 PM EST

Filing Impact

(Neutral)

Filing Sentiment

(Neutral)How Sentiment works

Sentiment and the balance of points

Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.

How Sentiment works How the balance works

Form Type

Rhea-AI Filing Summary

Cytokinetics Inc. (CYTK) reported that Fady Ibraham Malik, EVP Research & Development, exercised options covering 3,500 common shares on November 3, 2026, at a $7.80 exercise price, and sold 3,500 shares at $62.93 per share that day under a Rule 10b5-1 plan. The option record reported 12,886 underlying shares following the exercise.

Insider Trade Summary 10b5-1

Exercise and Sale: 3,500 shares ($193K approx. pre-tax spread)

Exercise and Sale 3 txns

Insider Malik Fady Ibraham

Role EVP Research & Development

Sold 3,500 shs ($220K)

Approx. gross sale proceeds $220K

Approx. exercise cost $27K

Approx. pre-tax spread $193K

Type	Security	Shares	Price	Value
Exercise	Non-Qualified Stock Option (Right to Buy)	3,500	$0.00	$0.00
Exercise	Common Stock	3,500	$7.80	$27K
Sale	Common Stock	3,500	$62.93	$220K

Holdings After Transaction: Non-Qualified Stock Option (Right to Buy) — 12,886 contracts (Direct); Common Stock — 153,902 shares (Direct)

Key Figures

Shares covered by options exercised: 3,500 common shares Exercise price: $7.80 per share Shares sold: 3,500 shares +2 more

5 metrics

Shares covered by options exercised 3,500 common shares November 3, 2026

Exercise price $7.80 per share Options exercised November 3, 2026

Shares sold 3,500 shares November 3, 2026

Sale price $62.93 per share Sale on November 3, 2026

Underlying shares in options following exercise 12,886 shares Reported following the November 3, 2026 transaction

Key Terms

Non-Qualified Stock Option, Rule 10b5-1 plan, Derivative security

3 terms

Non-Qualified Stock Option financial

"Non-Qualified Stock Option (Right to Buy)"

A non-qualified stock option (NSO) is a contract that lets an employee or service provider buy company shares at a fixed price for a set period, like a voucher to purchase stock later at today’s price. It matters to investors because exercising NSOs creates ordinary income for the holder and can increase share count, affecting a company’s earnings and ownership mix; think of it as a future sale that can dilute existing shareholders and has immediate tax consequences for the recipient.

Rule 10b5-1 plan regulatory

"Transactions affirmed under a Rule 10b5-1 trading plan"

A Rule 10b5-1 plan is a prearranged, written schedule that lets corporate insiders buy or sell company stock at set times or amounts, even if they later learn material nonpublic information. Think of it like setting an automatic thermostat for trades: it creates a clear record that trades were planned in advance, reducing the risk of insider-trading accusations and helping investors trust that insider transactions are routine rather than based on secret information.

Derivative security financial

"Exercise or conversion of derivative security"

A derivative security is a financial contract whose value comes from the price or performance of something else, such as a stock, bond, commodity, or market index. For investors it acts like an insurance policy or a wager: it can be used to protect against losses, lock in prices, or amplify gains and losses, so it can change a portfolio’s risk and potential return without owning the underlying asset directly.

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

How many CYTK shares did Fady Ibraham Malik sell, and at what price?

Fady Ibraham Malik sold 3,500 shares at $62.93 per share on November 3, 2026. The sale was reported under a Rule 10b5-1 trading plan.

What were the terms of the CYTK option exercise?

Fady Ibraham Malik exercised options covering 3,500 common shares at a $7.80 exercise price on November 3, 2026. The option record reported 12,886 underlying shares following the transaction.

AI-generated analysis. How Rhea-AI works. Not financial advice.

Form 4 Insider Transactions: What Each Field Means →

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Malik Fady Ibraham

(Last)

(First)

(Middle)

350 OYSTER POINT BLVD

(Street)

SOUTH SAN FRANCISCO

CALIFORNIA

94080

(City)

(State)

(Zip)

UNITED STATES

(Country)

2. Issuer Name and Ticker or Trading Symbol
CYTOKINETICS INC [ CYTK ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

	Director	10% Owner
X	Officer (give title below)	Other (specify below)
	EVP Research & Development

2a. Foreign Trading Symbol

3. Date of Earliest Transaction (Month/Day/Year)
11/03/2026

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

4. If Amendment, Date of Original Filed (Month/Day/Year)

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	Code	V	Amount	(A) or (D)	Price		6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
Common Stock	11/03/2026		M		3,500	A	$7.8	157,402	D
Common Stock	11/03/2026		S		3,500	D	$62.93	153,902	D

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares	8. Price of Derivative Security (Instr. 5)		10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
Non-Qualified Stock Option (Right to Buy)	$7.8	11/03/2026		M			3,500	03/27/2018	02/27/2028	Common Stock	3,500	$0	12,886	D

Explanation of Responses:

	/s/ John O. Faurescu, attorney-in-fact for Dr. Malik	11/03/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 4: SEC 1474 (03-26)

Source: View Original Filing on SEC EDGAR